iSTAR Medical

Executive Summary

iSTAR Medical is a Belgian medtech company dedicated to developing breakthrough eye care solutions for glaucoma, a leading cause of blindness. Its flagship product, MINIject®, is a minimally invasive glaucoma surgery (MIGS) implant designed for superior bio-integration. Unlike traditional glaucoma implants, MINIject® leverages a unique micro-porous structure that promotes tissue integration, potentially reducing fibrosis and improving long-term outcomes. The company, founded in 2023, has already achieved regulatory approval for MINIject® in Europe, positioning it to capture a share of the growing MIGS market. With an aging population and rising glaucoma prevalence, iSTAR Medical is well-placed to address significant unmet clinical needs. Despite its promising technology, iSTAR Medical faces challenges common to early-stage medtech firms, including commercial rollout execution, market adoption, and competition from established players. As a private company, financial details are limited, but successful commercialization and potential partnership deals could drive valuation. The next 12 months are critical for demonstrating real-world adoption and scaling production. If iSTAR can secure key opinion leader endorsements and initial sales traction, it may attract strategic investors or acquisition interest. The company’s focus on bio-integration offers a differentiated value proposition in the increasingly crowded MIGS space.

Upcoming Catalysts (preview)

• Q3 2026First commercial sales report or distribution partnership announcement70% success
• Q4 2026FDA submission or IDE approval for U.S. clinical trial40% success
• Q2 2026Publication of long-term clinical data for MINIject® at major ophthalmology conference80% success